Core Viewpoint - A class action lawsuit has been filed against Ardent Health, Inc. and certain officers for alleged violations of federal securities laws during the Class Period from July 18, 2024, to November 12, 2025 [1][2]. Group 1: Allegations and Financial Impact - The lawsuit claims that Ardent Health's Q3 2025 revenue was overstated due to inadequate assessments of accounts receivable collectability following a transition to a new revenue accounting system [3]. - The company's 2025 EBITDA guidance was allegedly overstated and would be reduced by $57.5 million at the midpoint, approximately 9.6%, due to persistent industry-wide cost pressures, including payer denials [3]. - As a result, statements made by the defendants regarding the company's business, operations, and prospects were materially false and misleading [3]. Group 2: Investor Actions and Legal Representation - Investors who suffered losses in Ardent have until March 9, 2026, to request the Court to appoint them as lead plaintiff, although sharing in any recovery does not require serving as lead plaintiff [4]. - Bronstein, Gewirtz & Grossman, LLC represents investors on a contingency fee basis, meaning they will only seek reimbursement for expenses and attorneys' fees if successful [5]. - The firm has a strong track record, having recovered hundreds of millions of dollars for investors nationwide, emphasizing their commitment to restoring investor capital and ensuring corporate accountability [6].
Bronstein, Gewirtz & Grossman LLC Urges Ardent Health, Inc. Investors to Act: Class Action Filed Alleging Investor Harm